Anti-pancreatic autoimmunity and Graves' disease: Study of a cohort of 600 Caucasian patients

European Journal of Endocrinology

Volumn 137, Issue 5, 1997, Pages 503-510

  Maugendre, Didier ^a   Vérité, Franck ^b   Guilhem, Isabelle ^a   Genetet, Bernard ^c   Allannic, Hubert ^a   Delamaire, Maryvonne ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b Centre Rêgional de Transfusion Sanguine   (France)

^c Inst de Rech Contre le Cancer IRCC   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE DECARBOXYLASE; INSULIN ANTIBODY; PANCREAS ISLET CELL ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; DIAGNOSIS; ETIOLOGY; FAMILY HISTORY; FEMALE; FOLLOW UP; GRAVES DISEASE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUMORAL IMMUNITY; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SCHOOL CHILD;

EID: 1842294623     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1370503     Document Type: Article

References (48)

1. Gorsuch AN, Spencer KM, Lister J, Mcnally JM, Dean BM, Bottazzo GF et al. Evidence for a long prediabetic period in type 1 diabetes mellitus. Lancet 1981 2 1363-1365.
2. Tarn AC, Thomas JM, Dean BM, Bottazzo GF & Gale EAM. Predicting insulin-dependent diabetes. Lancet 1988 1 845-850.
3. Betterle C, Zanette F, Pedini B, Presotto F, Rapp B, Monciotti CM et al. Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives. Diabetologia 1984 26 431-436.
4. Betterle C, Presotto F & Pedini B. Islet cell and insulin autoantibodies in organ-specific autoimmune patients. Their behaviour and predictive value for the development of type 1 diabetes mellitus. A 10-year follow-up study. Diabetologia 1987 30 292-297.
5. Bosi E, Becker F, Bonifacio E, Wagner R, Collins P, Gale EAM et al. Progression to type 1 diabetes in autoimmune endocrine patients with islet cell antibodies. Diabetes 1991 40 977-984.
6. Wagner R, Genovese S, Bosi E, Becker F, Bingley PJ, Bonifacio E et al. Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia 1994 37 365-371.
7. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990 347 151-156.
8. Kawasaki E, Takino H, Yano M, Uotani S, Matsumoto K, Takao Y et al. Autoantibodies to glutamic acid decarboxylase in patients with IDDM and autoimmune thyroid disease. Diabetes 1994 43 80-86.
9. Kawasaki E, Abiru N, Yano M, Uotani S, Matsumoto K, Matsuo H et al. Autoantibodies to glutamic acid decarboxylase in patients with autoimmune thyroid disease: relation to competitive insulin autoantibodies. Journal of Autoimmunity 1995 8 633-643.
10. Hallengren B, Falorni A, Landin-Olsson M, Lernmark A, Papadopoulos KI & Sundkvist G. Islet cell and glutamic acid decarboxylase antibodies in hyperthyroid patients: at diagnosis and following treatment. Journal of Internal Medicine 1996 239 63-68.
11. Payton MA, Hawkes J & Christie M. Relationship of the 37000-and 40000-Mr tryptic fragments of islet antigens in insulin-dependent diabetes to the protein tyrosine phosphatase-like molecule IA-2 (ICA512). Journal of Clinical Investigation 1995 96 1506-1511.
12. Passini N, Larigan JD, Genovese S, Appella E, Sinigaglia F & Rogge L. The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2. Proceedings of the National Academy of Sciences of the USA 1995 92 9412-9416.
13. Bonifacio E, Lampasona V, Genovese S, Ferrari M & Bosi E. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40k autoantigen and a target of islet-cell antibodies. Journal of Immunology 1995 155 419-426.
14. Lu J, Xie H, Chen ZJ, Borovitskaya AE, Maclaren NK, Notkins AL et al. Identification of a second transmembrane protein tyrosine phosphatase IA-2β, as an autoantigen in insulin-dependent diabetes mellitus: precursor of the 37-kDa tryptic fragment. Proceedings of the National Academy of Sciences of the USA 1996 93 2307-2311.
15. Hawkes CJ, Wasmeier C, Christie MR & Hutton JC. Identification of the 37-kDa antigen in IDDM as a tyrosine phosphatase-like protein (phogrin) related to IA-2. Diabetes 1996 45 1187-1192.
16. Christie M, Genovese S, Cassidy D, Bosi E, Brown TJ, Lai M et al. Antibodies to islet 37K antigen, but not glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994 43 1254-1259.
17. Madec AM, Laurent MC, Lorcy Y, Leguerrier AM, Rostagnat-Stefanutti A, Orgiazzi J et al. Thyroid stimulating antibody: an aid to the strategy of treatment of Graves' disease. Clinical Endocrinology 1984 21 247-255.
18. Madec AM, Allannic H, Genetet N, Gueguen M, Genetet B, Fauchet R et al. T lymphocyte subsets in various stages of hyperthyroid Graves' disease: effect of carbimazole treatment and relationship with thyroid stimulating antibody levels or HLA status. Journal of Clinical Endocrinology and Metabolism 1986 62 117-121.
19. Allannic H. Strategy for antithyroid drugs therapy in Graves' disease. Hormone Research 1987 26 146-153.
20. Allannic H, Fauchet R, Orgiazzi J, Madec AM, Genetet B, Lorcy Y et al. Antithyroid drugs and Graves' disease: a prospective randomized evaluation of the efficacy of treatment duration. Journal of Clinical Endocrinology and Metabolism 1990 70 675-679.
21. Bottazzo GF. Florin-Christensen A & Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974 2 1279-1283.
22. Pilcher C & Elliott RB. Improved sensitivity of islet cell cytoplasmic antibody assay in diabetics. Lancet 1984 1 1352.
23. Bonifacio E, Lernmark A & Dawkins L. Serum exchange and the use of dilutions have improved precision of measurement of islet cell antibodies. Journal of Immunological Methods 1988 106 83-88.
24. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK et al. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983 222 1337-1339.
25. Christie MR, Landin-Olsson M, Sundkvist G, Dahhquist O, Lermnark A & Baekkeskov S. Antibodies to a Mr-64000 islet cell protein in Swedish children with newly diagnosed type 1 (insulin-dependent) diabetes. Diabetologia 1988 31 597-602.
26. Christie MR, Tun RYM, Lo SSS, Cassidy D, Brown TJ, Hollands J et al. Antibodies to GAD and tryptic fragments of islet 64K antigen as distinct markers for development of IDDM. Studies with identical twins. Diabetes 1992 41 782-787.
27. Thivolet CH, Tappaz M, Durand A, Petersen J, Stefanutti A, Chatelain P et al. Glutamic acid decarboxylase (GAD) autoantibodies are additional predictive markers of type 1 (insulin-dependent) diabetes mellitus in high risk individuals. Diabetologia 1992 35 570-576.
28. Schmidli RS, Colman PG, Bonifacio E, Bottazzo GF, Harrison LC & participating laboratories. High level of concordance between assays for glutamic acid decarboxylase antibodies. The First International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes 1994 43 1005-1009.
29. Schmidli RS, Colman PG, Bonifacio E & participating laboratories. Disease sensitivity and specificity of 52 assays for glutamic acid decarboxylase antibodies. The Second International Glutamic Acid Decarboxylase Antibody Workshop. Diabetes 1995 44 636-640.
30. Delamaire M, Timsit J, Caillat-Zuckman S, Maugendre D, Roussely H, Semana G et al. HLA control of anti-islet cell humoral response heterogeneity in patients with type 1 diabetes. Journal of Autoimmunity 1995 8 645-657.
31. Christie MR, Vohra G, Champagne P, Daneman D & Delovitch TL. Distinct antibody specificities to a 64-kD islet cell antigen in type 1 diabetes as revealed by trypsin treatment. Journal of Experimental Medicine 1990 172 789-794.
32. Atkinson MA, Kaufman DL, Newman D, Tobin AJ & Maclaren NK. Islet cell cytoplasmic autoantibody reactivity to glutamate decarboxylase in insulin-dependent diabetes. Journal of Clinical Investigation 1993 91 350-356.
33. Genovese S, Bonifacio E, McNally JMM, Dean M, Wagner R, Bosi E et al. Distinct cytoplasmic islet cell antibodies with different risks for type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1992 35 385-388.
34. Mouradian M & Abourizk N. 1983 Diabetes mellitus and thyroid disease. Diabetes Care 1983 6 512-520.
35. Levy-Marchal C, Tichet J, Fajardy I, Gu XF, Dubois F & Czernichow P. Islet cell antibodies in normal French schoolchildren. Diabetologia 1992 35 577-582.
36. Chaillous L, Delamaire M, Elmansour A, Maugendre D, Rohmer V, Joseph MG et al. Combined analysis of islet cell antibodies which crossreact with mouse pancreas, antibodies to the 64000 islet protein, and antibodies to glutamate decarboxylase, in subjects at risk for IDDM. Diabetologia 1994 37 491-499.
37. Irvine WJ, McCallum CJ, Gray RS, Campbell CJ, Duncan LPJ, Farquar JW et al. Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type. Diabetes 1977 26 138-147.
38. Yamaguchi Y, Chikuba N, Ueda Y, Yamamoto H, Yamasaki H, Nakanishi T et al. Islet cell antibodies in patients with autoimmune thyroid disease. Diabetes 1991 40 319-322.
39. Betterle C, Presotto F, Magrin L, Pedini B, Caretto A & Zanchetta R. The natural history of pre-type 1 (insulin-dependent) diabetes mellitus in patients with autoimmune endocrine diseases. Diabetologia 1994 37 95-103.
40. Riley WJ, Winer A & Goldstein D. Coincident presence of thyrogastric autoimmunity at onset of type 1 diabetes. Diabetologia 1983 24 418-421.
41. Chaillous L, Delamaire M, Martignat L, Maugendre D, Marre M, Mathieu E et al. Combined analysis of islet cell antibodies which crossreact with mouse pancreas, antibodies to the 64 000 islet protein, and antibodies to glutamate decarboxylase, in type 1 diabetic patients. Diabetes Care 1994 17 1115-1123.
42. Aanstoot HJ, Sigurdsson E, Jaffe M, Shi Y, Christgau S, Grobbee D et al. Value of antibodies to GAD 65 combined with islet cell cytoplasmic antibodies for predicting IDDM in a childhood population. Diabetologia 1994 37 917-924.
43. Lernmark A. Glutamic acid decarboxylase - gene to antigen to disease. Journal of Internal Medicine 1996 240 259-277.
44. Christie M, Brown TJ & Cassidy D. Binding of antibodies in sera from type 1 diabetic patients to glutamate decarboxylase from rat tissues. Evidence for antigenic and non-antigenic forms of the enzyme. Diabetologia 1992 35 380-384.
45. Nuovo JA, Baker JR, Wartofsky L, Lukes YG & Burman KD. Autoantibodies to insulin are present in sera of patients with autoimmune thyroid disease. Diabetes 1988 37 317-320.
46. Wilkin T, Mirza I, Armitage M, Casey C & Scott-Morgan L. Insulin autoantibody polymorphisms with greater discrimination for diabetes in human. Diabetologia 1988 31 670-674.
47. Wagner R, McNally JM, Bonifacio E, Genovese S, Foulis A, McGill M et al. Lack of immunochemical changes in the islets of nondiabetic. autoimmune, polyendocrine patients with β-selective GAD-specific islet cell antibodies. Diabetes 1994 43 851-856.
48. Huang W, Connor E, Dela Rosa T, Muir A, Schatz D, Silverstein J et al. Although DR 3-DQB1*0201 may be associated with multiple component diseases of the autoimmune polyglandular syndromes, the human leukocyte antigen DR4-DQB1*0302 haplo-type is implicated only in β-cell autoimmunity. Journal of Clinical Endocrinology and Metabolism 1996 81 2559-2563.